Nautilus Biotechnology launched its Iterative Mapping Early Access Program and named Baylor College of Medicine its first customer for the Voyager single‑molecule proteomics platform. Baylor will apply Voyager to identify aberrant protein isoforms in tumors and develop computational toolkits to integrate isoform‑resolved proteomics with transcriptomics. Nautilus unveiled the Voyager platform publicly at US HUPO after field tests at the Buck Institute; the company positions this system to resolve full‑length proteoforms inaccessible to conventional mass spec. Baylor’s NIH‑funded study aims to benchmark Voyager data against shotgun datasets to improve isoform detection and clinical proteomics workflows. The collaboration provides a targeted early commercial validation for Nautilus ahead of a wider launch planned for late 2026 and may accelerate adoption of single‑molecule proteomics in oncology biomarker research.